ScholarIQanswers from OpenAlex

Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan

PaperCitations, authors & open-access status

Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan have?

ScholarIQcitation count

Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan has 4 citations in the OpenAlex counts ScholarIQ stores.

When was Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan published?

ScholarIQyear

Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan has 2021 year in the ScholarIQ index.

Open the OpenAlex record →

What is the open-access status of Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan?

ScholarIQoa status

Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan has gold oa status in the ScholarIQ index.

Open the OpenAlex record →

What is the DOI of Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan?

ScholarIQdoi

The DOI for Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan is on the source record.

Open the DOI →

What is the OpenAlex record for Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan?

ScholarIQopenalex

The OpenAlex for Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan is on the source record.

Open the OpenAlex →